Mexico and Brazil do not plan to restrict access to AstraZeneca’s COVID-19 vaccine after the UK Drug Adviser recommended doing so at a potential risk of blood clots.
The statements come after the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) recommended that the vaccine is only used in people over 30 years of age due to the potential connection to rare blood clots.
The agency said it reviewed 79 reports of rare blood clots following the administration of the vaccine with 19 deaths. Eleven of the 19 who died were under 50, while three were under 30.
Meanwhile, Brazilian health regulator Anvisa said the benefits of the vaccine outweigh the risks and recommended continued use. The news committee noted that Brazil has administered over 4 million shots of the vaccine and has only recorded 47 coagulation events.
The UK recommendation came on the same day that the European Medicines Agency’s (EMA) safety panel concluded that a “possible link“Between rare blood clots and the vaccine existed.
Concerns about blood clots in a small number of patients resulted in more than a dozen countries suspending the use of the vaccine last month. Oxford University stopped a clinical trial testing the vaccine in 300 children aged 6 to 17, while awaiting the MHRA’s opinion on the reports of blood clots.
AstraZeneca has claimed that its evidence has not found a causal link between the vaccine and blood clots.